

A woman's profile is shown in a three-quarter view, facing left. Her hair is pulled up into a bun. Overlaid on her face and neck is a complex digital network of glowing blue and yellow lines and dots, resembling a molecular or data structure. The background is dark grey.

29<sup>TH</sup> CONGRESS

**EADVIRTUAL**

29<sup>th</sup> – 31<sup>st</sup> October 2020

NEW FRONTIERS  
IN DERMATOLOGY AND VENEREOLOGY

## Free Communications sessions

THE COMPLETE LIST OF ABSTRACTS ACCEPTED AS FREE COMMUNICATIONS FOR  
THE 29TH EADV CONGRESS, 29TH – 31ST OCTOBER, 2020

## **FC01**     *Free Communications - Acne and related disorders*

**FC01.01**     **Impaired lysosomal activity in PEN2 and NCSTN deficient keratinocytes is responsible for hyperkeratosis and inflammation in hidradenitis suppurativa**

Cecile Nait-Meddour (Creteil, France)

**FC01.02**     **Molecular taxonomy of HS provides evidence of key molecular mediators, gender-specificity and innate immunity drivers**

Andre da Costa (Gothenburg, Sweden)

**FC01.03**     **PBI-HS: Validation study of a new disease specific Instrument to assess patient benefit from treatment by patients with hidradenitis suppurativa**

Natalie Kirsten (Hamburg, Germany)

**FC01.04**     **INCB054707, a Janus kinase 1 Inhibitor, for patients with moderate to severe hidradenitis suppurativa: Results from two Phase 2 studies**

Afsaneh Alavi (Rochester, United States)

**FC01.05**     **Surgical restructuring of hidradenitis suppurativa with primary wound closure under adalimumab, case series documented benefit**

Gefion Girbig (Hamburg, Germany)

**FC01.06**     **Personalising Acne: Consensus of Experts (PACE). Patient-centred management of acne – what is missing from the guidelines?**

Alison Layton (Harrogate, United Kingdom)

**FC01.07**     **The impact of personal protective equipment on acne vulgaris and rosacea during the COVID-19 pandemics**

Giovanni Damiani (Milan, Italy)

**FC01.08**     **Acne in pregnancy: A prospective multicentre, cross-sectional study of 295 patients in Turkey**

Ömer Kutlu (Uşak, Turkey)

**FC01.09**     **Isotretinoin in acne: Seven fold increase in treatment-limiting depressive mood changes in those with a history of depression**

Sanaa Butt (Dundee, United Kingdom)

**FC01.10**     **Reduction of post-acne atrophic scars through transepidermal administration of a sterile solution with polynucleotides**

Sebastian Podlipnik (Barcelona, Spain)

## **FC02**      *Free Communications - Psoriasis I*

- FC02.01**      **Pharmacovigilance of systemic antipsoriatic treatment: Results from more than 15,000 patient years in the German Psoriasis Registry PsoBest**  
Christina Sorbe (Hamburg, Germany)
- FC02.02**      **The impact of COVID-19 in a large population of psoriatic patients undergoing biologics**  
Giovanni Damiani (Milan, Italy)
- FC02.03**      **Systemic or biologic treatment in psoriasis patient does not increase the risk of a severe form of COVID-19**  
Anne-Claire Fougerousse (Saint Mandé, France)
- FC02.04**      **Long-term drug survival in adult patients with moderate to severe chronic plaque psoriasis treated with biologic therapies: Real-world data from a large nationwide health maintenance organisation**  
Lev Pavlovsky (Petach Tikva, Israel)
- FC02.05**      **Safety and efficacy of an orally administered, single strain commensal microbe in psoriasis after 28 days of therapy: EDP1815**  
Douglas Maslin (Cambridge, United Kingdom)
- FC02.06**      **Ixekizumab shows early and sustained resolution of nail psoriasis in patients with psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from a multicentre, randomised, open-label, rater-blinded study (SPIRIT-H2H)**  
Kristian Reich (Hamburg, Germany)
- FC02.07**      **Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from phase 2 and 3 clinical trials**  
Kristian Reich (Hamburg, Germany)
- FC02.08**      **Secukinumab demonstrated high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: One-year results**  
Christine Bodemer (Paris, France)
- FC02.09**      **Sustained response after withdrawal of guselkumab therapy in patients with moderate-to-severe psoriasis: a post hoc analysis of the VOYAGE-2 trial**  
Curdin Conrad (Lausanne, Switzerland)
- FC02.10**      **BMS-986165, an Oral, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, Reduces Psoriasis Area and Severity Index (PASI) Component Scores Across Body Regions in Patients With Psoriasis**  
Alan Menter (Dallas, TX, United States)

## **FC03**      *Free Communications - Psoriasis II*

**FC03.01**      **Treatment modalities and risk of adverse events association with biologics therapy: A 10-year observational review of the Australasian Psoriasis Registry**  
Brent Doolan (Darlinghurst, Australia)

**FC03.02**      **Psoriasis, pregnancy, and shared decision making: Challenges experienced by dermatologists**  
Jenny Murase (Cupertino, United States)

**FC03.03**      **Real-world study of the impact of the COVID-19 pandemic on patients with psoriasis**  
Bruno Halioua (Paris, France)

**FC03.04**      **Real-world data of SB5 (adalimumab biosimilar) treatment in patients with psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)**  
Giampiero Girolomoni (Verona, Italy)

**FC03.05**      **Roflumilast cream (ARQ-151) improved itch severity and itch-related sleep loss in adults with chronic plaque psoriasis in a phase 2b Study**  
Linda Stein Gold (Detroit, United States)

**FC03.06**      **Bimekizumab versus ustekinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3 BE VIVID trial**  
Bruce Strober (Avon, United States)

**FC03.07**      **Interim analysis of the non-interventional study SKILL: Dimethyl fumarate (DMF) as long-term treatment for moderate-to-severe plaque psoriasis and its impact on sensitive areas affected by psoriasis**  
Matthias Augustin (Hamburg, Germany)

**FC03.08**      **A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis**  
Christopher Tehlirian (Cambridge, MA, United States)

**FC03.09**      **Efficacy and safety of long-term risankizumab treatment for nail, scalp, and palmoplantar psoriasis: An interim analysis from the open-label extension LIMMitless Trial**  
Boni E. Elewski (Birmingham, United States)

**FC03.10**      **Efficacy and safety of BI 730357, a novel oral ROR $\gamma$ t antagonist, in patients with moderate-to-severe plaque psoriasis in a Phase II proof-of-concept, dose-ranging study**  
Kristian Reich (Hamburg, Germany)

## **FC04**    *Free communications - Therapy I*

**FC04.01**    **Topical administration of 1% glycopyrronium bromide (GPB) cream is efficient and safe in treatment of primary axillary hyperhidrosis: A randomized placebo-controlled trial**

Rolf-Markus Szeimies (Recklinghausen, Germany)

**FC04.02**    **Melanogenic effect of Dersimelagon (MT-7117), an oral melanocortin 1 receptor (MC1R) agonist: Phase 2 clinical study results**

Kirstine Belongie (Jersey City, United States)

**FC04.03**    **A survey of UVA protection levels of SPF 50+ dermocosmetic face sunscreens on the European market: Same label, different levels of efficacy**

Martin Josso (Chevilly Larue, France)

**FC04.04**    **Efficacy and tolerability of balneotherapy on skin complications after breast cancer surgery and radiotherapy: Results of a randomised, controlled, open-label trial**

Ivan Krakowski (Bégles, France)

**FC04.05**    **BLU-5937, a potent and selective P2X3 receptor antagonist, presents a promising new approach for the treatment of pruritus in atopic dermatitis patients**

Nathalie Chauret (Laval, Canada)

**FC04.06**    **Vixarelimab reduced pruritus, improved nodules, and was well-tolerated in patients with Prurigo Nodularis in a Phase 2a, randomized, double-blind, placebo-controlled study**

Howard Sofen (Los Angeles, United States)

**FC04.07**    **DECISA Project (DERmatology Clinics in Italy: Survey on Alitretinoin): A real-life retrospective multicenter trial on 425 subjects with severe chronic hand eczema**

Massimo Milani (Caronno Pertusella, Italy)

**FC04.08**    **Pulsed-dye laser-mediated photodynamic therapy is less effective than conventional photodynamic therapy for actinic field cancerization: A randomized half-side comparative study**

Vivian Lindholm (Helsinki, Finland)

**FC04.09**    **Topical Nitrizinc Complex Solution (NZCS) compared to cryotherapy for the treatment of anogenital warts (AGW) in everyday practice: A randomized multicentre study**

Marco Cusini (Milan, Italy)

**FC04.10**    **Improvements in genital ulcers and quality of life in patients with active Behcet's Syndrome: Results from analysis of randomized controlled trials with apremilast**

Gülen Hatemi (Istanbul, Turkey)

## **FC05**      *Free Communications - Therapy II*

**FC05.01**      **The Global Guidelines in Dermatology Mapping Exercise (GUIDEMAP): a scoping review of dermatology clinical practice guidelines**

William Haw (Manchester, United Kingdom)

**FC05.02**      **British Association of Dermatologists guidelines for the management of people with vitiligo 2020**

Viktoria Eleftheriadou (Nottingham, United Kingdom)

**FC05.03**      **Oral Cyclosporine is effective in stabilizing active vitiligo: Results of a randomised controlled trial**

Hitaishi Mehta (Chandigarh, India)

**FC05.04**      **Efficacy of topical crisaborole for treating mild-to-moderate seborrheic dermatitis**

Sandra Pena (Birmingham, United States)

**FC05.05**      **Effectiveness and safety of zinc oxide nanoparticle-coated socks compared to uncoated socks for the prevention of unpleasant foot odour: A double-blinded, randomized, controlled trial study**

Punyawee Ongsri (Bangkok, Thailand)

**FC05.06**      **Microneedling improves minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes**

Andy Goren (Irvine, CA, United States)

**FC05.07**      **Evaluation of the efficacy of an emollient containing urea in adults suffering from mild to moderate keratosis pilaris**

Anne-Laure Demessant-Flavigny (Levallois-Perret, France)

**FC05.08**      **Bimekizumab efficacy and safety versus adalimumab in patients with moderate to severe plaque psoriasis: Results from a multicentre, randomised, double-blinded active comparator-controlled phase 3 trial (BE SURE)**

Richard Warren (Manchester, United Kingdom)

**FC05.09**      **Clinical, instrumental and ex-vivo evaluation of a product containing 5% low molecular weight hyaluronic acid associated with organic silicium, 0,1% of pure retinol, phospholipids and polyssacharides with dual action in the improvement of skin elasticity, firmness and wrinkles**

Francine Papaiordanou (Guarulhos, Brazil)

**FC05.10**      **The utility of procollagen-3 N-terminal peptide measurement in methotrexate treated psoriasis patients in a real world setting.**

Miriam O'Connor (Drogheda, Ireland)

## **FC06**      *Free Communications - Miscellaneous I*

**FC06.01**      **Melanoma detection during Covid-19 in central London**

Anna Schauer (London, United Kingdom)

**FC06.02**      **Comparison of total body nevus count in multiple primary melanoma and single primary melanoma patients: A prospective single centre study**

Banu Farabi (Ankara, Turkey)

**FC06.03**      **Considerable family impact of moderate-to-severe AD in children aged < 12 years: Results from the PEDISTAD observational study**

Amy Paller (Chicago, United States)

**FC06.04**      **Sleep behavior during propranolol treatment for infantile hemangioma - a prospective, controlled study.**

Martin Theiler (Zurich, Switzerland)

**FC06.05**      **The role of line field confocal optical coherence tomography in the diagnosis of vesicobullous diseases**

Linda Tognetti (Siena, Italy)

**FC06.06**      **Assessing HRQoL in chronic wounds across countries: The cross-cultural validity of the revised Wound-QoL questionnaire**

Catharina von Stülpnagel (Hamburg, Germany)

**FC06.07**      **Automatic image quality analysis in the context of AI support in dermoscopy**

Jonas De Vylder (Kortrijk, Belgium)

**FC06.08**      **The eye of the provider; an 18-year case series of periocular dermatitis**

Mitesh Patel (Birmingham, United Kingdom)

**FC06.09**      **Acute dermatology in a district general hospital: An audit of knowledge and confidence levels regarding acute dermatology amongst the wider medical team.**

Tien Thuy Tran (London, United Kingdom)

**FC06.10**      **Nurse-led systemics review clinics - a service improvement initiative within a UK dermatology department**

Victoria Campbell (Belfast, United Kingdom)

## **FC07**      *Free Communications - Miscellaneous II*

**FC07.01**      **Audit of a regional teledermatology referral system - our experience from pilot to a fully functional service**

Victoria Vilenchik (Bristol, United Kingdom)

**FC07.02**      **Optimizing skin cancer detection in the general population: An early access lesion-directed consultation**

Sofie Mylle (Ghent, Belgium)

**FC07.03**      **Translating the WHA resolution in a member state: Development, testing, and evaluation of interventions against stigmatisation of people with visible skin diseases**

Rachel Sommer (Hamburg, Germany)

**FC07.04**      **Is the patient doing the homework? Comparing sun protection practices and knowledge between patients who have had skin cancer and patients who have not**

Luiza Bertholdi (Curitiba, Brazil)

**FC07.05**      **European Prurigo Project: Patient perspective on therapeutic needs and satisfaction**

Manuel Pedro Pereira (Munster, Germany)

**FC07.06**      **Clinical application of in vivo ultra-high cellular resolution full-field optical coherence tomography in the diagnosis of skin tumours and inflammatory skin diseases**

Yen-jen Wang (Taipei, Taiwan)

**FC07.07**      **Pediatric drug reaction with eosinophilia and systemic symptoms: A systematic review of the literature, with a focus on relapsing cases**

Perla Zeinaty (Beirut, Lebanon)

**FC07.08**      **Validation of a model combining clinicopathologic risk factors and a gene expression profile to identify primary melanoma patients who can safely forgo sentinel lymph node biopsy**

Alexander Meves (Rochester, United States)

**FC07.09**      **Specific cutaneous infiltrates in patients with haematological neoplasms: A retrospective study with 49 patients**

Rebeca Calado (Coimbra, Portugal)

**FC07.10**      **Super-high-magnification dermoscopy can identify atypical melanocytes**

Elisa Cinotti (Siena, Italy)

## **FC08**      *Free Communications - Atopic dermatitis and urticaria*

- FC08.01**      **The economic burden of moderate-to-severe atopic dermatitis in Europe: Analysis of the 2017 National Health and Wellness Survey**  
Giampiero Girolomoni (Verona, Italy)
- FC08.02**      **Treatment patterns and outcomes in patients with chronic urticaria during pregnancy: Results of the PREG-CU study, a UCARE Project**  
Emek Kocatürk Göncü (Istanbul, Turkey)
- FC08.03**      **Management of ocular manifestations in atopic dermatitis: A consensus meeting using a modified Delphi process**  
Jacob Thyssen (Hellerup, Denmark)
- FC08.04**      **Consistency of efficacy response across randomized, controlled Phase 2/3 clinical trials of abrocitinib monotherapy: JADE MONO-1, JADE MONO-2, and the Phase 2b Proof-of-Concept Trial**  
Jacob Thyssen (Hellerup, Denmark)
- FC08.05**      **Specifically targeting interleukin-13 with tralokinumab improved sleep in two Phase 3, randomised, double-blind, placebo-controlled trials in patients with atopic dermatitis**  
Jonathan Silverberg (Washington, United States)
- FC08.06**      **Impact of lebrikizumab on patient-reported outcomes in atopic dermatitis: prospective and exploratory post hoc analyses of a phase 2b clinical trial demonstrate clinically meaningful improvements**  
Emma Guttman-Yassky (New York, United States)
- FC08.07**      **The safety and efficacy of roflumilast cream 0.15% and 0.05% in atopic dermatitis: Phase 2 proof-of-concept study**  
Melinda Gooderham (Peterborough, Canada)
- FC08.08**      **Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Pooled analysis of two Phase 3, randomised, double-blind studies**  
Kim A. Papp (Waterloo, Ontario, Canada)
- FC08.09**      **Impact of targeting interleukin-13 on Staphylococcus aureus colonisation: results from a Phase 3, randomised, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis**  
Amy Paller (Chicago, United States)
- FC08.10**      **Ligelizumab achieves fast control of symptoms in more patients with chronic spontaneous urticaria compared with omalizumab: Analysis of the first 12 weeks of the Phase 2b study**  
Marcus Maurer (Berlin, Germany)